E. Roberts
YOU?
Author Swipe
View article: POS0823 UPTAKE OF INFLIXIMAB BIOSIMILARS AMONG U.S. RHEUMATOLOGY PRACTICES THROUGH 2022
POS0823 UPTAKE OF INFLIXIMAB BIOSIMILARS AMONG U.S. RHEUMATOLOGY PRACTICES THROUGH 2022 Open
Background The first infliximab biosimilar (infliximab-dybb) entered the U.S. market in 2016 and two additional products are now available (infliximab-axxq and infliximab-abda). Biosimilars have significant potential to slow drug spending;…